RecruitingPhase 1Phase 2NCT07010692

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas


Sponsor

Bruce Robinson, MD

Enrollment

100 participants

Start Date

May 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination treatment for skin cancers — specifically basal cell carcinoma and squamous cell carcinoma — using fractional laser therapy alongside a topical cream called tirbanibulin ointment, to see if it is an effective non-surgical option. **You may be eligible if...** - You have a biopsy-confirmed basal cell carcinoma or squamous cell carcinoma on your skin - Your skin cancer has not been previously treated by another method **You may NOT be eligible if...** - You are currently pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTirbanibulin ointment 1%

Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.

DEVICEnon-ablative fractional laser

Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.


Locations(1)

Bruce Robinson, MD

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07010692


Related Trials